Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aPBPM trial for delirium prevention in emergency general wards
jRCTs051220122Recruiting
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of blonanserin, ramelteon and lemborexant in delirium (2 arms). Primary endpoint: Incidence of delirium diagnosed with DSM-5 within 3 days of the start of the study. Started Nov 2022; status: recruiting.
02
Drugs
blonanserinramelteonlemborexant
03
Conditions
delirium
Beyond the preview
Go deeper on jRCTs051220122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220122.